{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:29:25Z","timestamp":1792690165742,"version":"4.5.0"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells with CRISPR\/Cas9-engineered CDH1 mutations, we identified synthetic lethality between E-cadherin deficiency and inhibition of the tyrosine kinase ROS1. Data from large-scale genetic screens in molecularly diverse breast tumor cell lines established that the E-cadherin\/ROS1 synthetic lethality was not only robust in the face of considerable molecular heterogeneity but was also elicited with clinical ROS1 inhibitors, including foretinib and crizotinib. ROS1 inhibitors induced mitotic abnormalities and multinucleation in E-cadherin\u2013defective cells, phenotypes associated with a defect in cytokinesis and aberrant p120 catenin phosphorylation and localization. In vivo, ROS1 inhibitors produced profound antitumor effects in multiple models of E-cadherin\u2013defective breast cancer. These data therefore provide the preclinical rationale for assessing ROS1 inhibitors, such as the licensed drug crizotinib, in appropriately stratified patients.<\/jats:p>\n                  <jats:p>Significance: E-cadherin defects are common in breast cancer but are currently not targeted with a precision medicine approach. Our preclinical data indicate that licensed ROS1 inhibitors, including crizotinib, should be repurposed to target E-cadherin\u2013defective breast cancers, thus providing the rationale for the assessment of these agents in molecularly stratified phase II clinical trials. Cancer Discov; 8(4); 498\u2013515. \u00a92018 AACR.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 371<\/jats:p>","DOI":"10.1158\/2159-8290.cd-17-0603","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:45:22Z","timestamp":1522629922000},"page":"498-515","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["E-Cadherin\/ROS1 Inhibitor Synthetic Lethality in Breast Cancer"],"prefix":"10.1158","volume":"8","author":[{"given":"Ilirjana","family":"Bajrami","sequence":"first","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Marlow","sequence":"additional","affiliation":[{"name":"3The Breast Cancer Now Research Unit, King's College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"van de Ven","sequence":"additional","affiliation":[{"name":"4Mouse Clinic for Cancer and Aging (MCCA) Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Brough","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen N.","family":"Pemberton","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Frankum","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Song","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumana","family":"Rafiq","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Konde","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragomir B.","family":"Krastev","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini","family":"Menon","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Campbell","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Gulati","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Kumar","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Pettitt","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Gurden","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Llorca","family":"Cardenosa","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"5Biomedical Research Institute INCLIVA, Hospital Clinico Universitario Valencia, University of Valencia, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Chong","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Gazinska","sequence":"additional","affiliation":[{"name":"3The Breast Cancer Now Research Unit, King's College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Wallberg","sequence":"additional","affiliation":[{"name":"6FACS Core Facility, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor J.","family":"Sawyer","sequence":"additional","affiliation":[{"name":"7Division of Cancer Studies, Guy's Hospital, King's College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley-Ann","family":"Martin","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spiros","family":"Linardopoulos","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"8Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Natrajan","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm J.","family":"Ryan","sequence":"additional","affiliation":[{"name":"9Systems Biology Ireland, University College Dublin, Dublin, Ireland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.B.","family":"Derksen","sequence":"additional","affiliation":[{"name":"10Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Jonkers","sequence":"additional","affiliation":[{"name":"11Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N.J.","family":"Tutt","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"3The Breast Cancer Now Research Unit, King's College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Ashworth","sequence":"additional","affiliation":[{"name":"12UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Lord","sequence":"additional","affiliation":[{"name":"1The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."},{"name":"2Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"2022060701161263200_bib1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"key":"2022060701161263200_bib2","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1038\/onc.2008.343","article-title":"Cadherins and cancer: how does cadherin dysfunction promote tumor progression?","volume":"27","author":"Jeanes","year":"2008","journal-title":"Oncogene"},{"key":"2022060701161263200_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ncb3136","article-title":"E-cadherin junctions as active mechanical integrators in tissue dynamics","volume":"17","author":"Lecuit","year":"2015","journal-title":"Nat Cell Biol"},{"key":"2022060701161263200_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-015-0517-z","article-title":"Lobular breast cancer: molecular basis, mouse and cellular models","volume":"17","author":"Christgen","year":"2015","journal-title":"Breast Cancer Res"},{"key":"2022060701161263200_bib5","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1200\/JCO.2015.64.0334","article-title":"Genomic characterization of primary invasive lobular breast cancer","volume":"34","author":"Desmedt","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022060701161263200_bib6","doi-asserted-by":"crossref","first-page":"18517","DOI":"10.1038\/srep18517","article-title":"Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer","volume":"6","author":"Michaut","year":"2016","journal-title":"Sci Rep"},{"key":"2022060701161263200_bib7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.steroids.2012.11.002","article-title":"Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems","volume":"78","author":"Sikora","year":"2013","journal-title":"Steroids"},{"key":"2022060701161263200_bib8","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO.2015.60.8133","article-title":"Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1\u201398 Trial","volume":"33","author":"Metzger Filho","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060701161263200_bib9","doi-asserted-by":"crossref","first-page":"nr S2\u201306","DOI":"10.1158\/1538-7445.SABCS14-S2-06","article-title":"Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study","volume":"75","author":"Knauer","year":"2015","journal-title":"Cancer Res"},{"key":"2022060701161263200_bib10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.prp.2016.05.002","article-title":"Lobular breast cancer: clinical, molecular and morphological characteristics","volume":"212","author":"Christgen","year":"2016","journal-title":"Pathol Res Pract"},{"key":"2022060701161263200_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.2005.03.111","article-title":"Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes","volume":"23","author":"Cristofanilli","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022060701161263200_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/sj.bjc.6605735","article-title":"Significance of E-cadherin expression in triple-negative breast cancer","volume":"103","author":"Kashiwagi","year":"2010","journal-title":"Br J Cancer"},{"key":"2022060701161263200_bib13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/ajcp\/aqw183","article-title":"Prognostic value of E-Cadherin and beta-catenin in triple-negative breast cancer","volume":"146","author":"Shen","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"2022060701161263200_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cell.2011.03.020","article-title":"Genetic interactions in cancer progression and treatment","volume":"145","author":"Ashworth","year":"2011","journal-title":"Cell"},{"key":"2022060701161263200_bib15","doi-asserted-by":"crossref","first-page":"19519","DOI":"10.1073\/pnas.1319583110","article-title":"Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins","volume":"110","author":"Davare","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161263200_bib16","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2022060701161263200_bib17","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1073\/pnas.1420785112","article-title":"PF-06463922 is a potent and selective next-generation ROS1\/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations","volume":"112","author":"Zou","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161263200_bib18","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N Engl J Med"},{"key":"2022060701161263200_bib19","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.celrep.2016.02.023","article-title":"Large-scale profiling of kinase dependencies in cancer cell lines","volume":"14","author":"Campbell","year":"2016","journal-title":"Cell Rep"},{"key":"2022060701161263200_bib20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.celrep.2015.03.050","article-title":"The proteomic landscape of triple-negative breast cancer","volume":"11","author":"Lawrence","year":"2015","journal-title":"Cell Rep"},{"key":"2022060701161263200_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-009-0460-8","article-title":"Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines","volume":"121","author":"Hollestelle","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2022060701161263200_bib22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nbt.3527","article-title":"Characterizing genomic alterations in cancer by complementary functional associations","volume":"34","author":"Kim","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2022060701161263200_bib23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/1471-2407-14-552","article-title":"E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition","volume":"14","author":"Chen","year":"2014","journal-title":"BMC Cancer"},{"key":"2022060701161263200_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10549-013-2415-3","article-title":"Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer","volume":"138","author":"Hollestelle","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2022060701161263200_bib25","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1093\/bioinformatics\/btr467","article-title":"ChimeraScan: a tool for identifying chimeric transcription in sequencing data","volume":"27","author":"Iyer","year":"2011","journal-title":"Bioinformatics"},{"key":"2022060701161263200_bib26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nbt.3080","article-title":"A comprehensive transcriptional portrait of human cancer cell lines","volume":"33","author":"Klijn","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2022060701161263200_bib27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cell.2016.08.041","article-title":"A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds","volume":"167","author":"Bruna","year":"2016","journal-title":"Cell"},{"key":"2022060701161263200_bib28","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/cncr.23190","article-title":"Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?","volume":"112","author":"Johnston","year":"2008","journal-title":"Cancer"},{"key":"2022060701161263200_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-0760(02)00074-2","article-title":"Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation","volume":"81","author":"Chan","year":"2002","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2022060701161263200_bib30","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1158\/0008-5472.CAN-13-2779","article-title":"Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response","volume":"74","author":"Sikora","year":"2014","journal-title":"Cancer Res"},{"key":"2022060701161263200_bib31","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/bjc.2014.61","article-title":"HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma","volume":"110","author":"Liu","year":"2014","journal-title":"Br J Cancer"},{"key":"2022060701161263200_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13046-015-0228-4","article-title":"Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition","volume":"34","author":"Megiorni","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"2022060701161263200_bib33","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.4161\/cc.10.23.18323","article-title":"Mechanism of action of the multikinase inhibitor Foretinib","volume":"10","author":"Dufies","year":"2011","journal-title":"Cell Cycle"},{"key":"2022060701161263200_bib34","doi-asserted-by":"crossref","first-page":"15399","DOI":"10.1073\/pnas.0807301105","article-title":"Loss of p120 catenin and links to mitotic alterations, inflammation, and skin cancer","volume":"105","author":"Perez-Moreno","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161263200_bib35","doi-asserted-by":"crossref","first-page":"13874","DOI":"10.1038\/ncomms13874","article-title":"p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis","volume":"7","author":"van de Ven","year":"2016","journal-title":"Nat Commun"},{"key":"2022060701161263200_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.yexcr.2007.07.024","article-title":"The regulatory or phosphorylation domain of p120 catenin controls E-cadherin dynamics at the plasma membrane","volume":"314","author":"Fukumoto","year":"2008","journal-title":"Exp Cell Res"},{"key":"2022060701161263200_bib37","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.274.51.36734","article-title":"Regulation of E-cadherin\/Catenin association by tyrosine phosphorylation","volume":"274","author":"Roura","year":"1999","journal-title":"J Biol Chem"},{"key":"2022060701161263200_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1242\/jcs.114.3.503","article-title":"Tyrosine phosphorylation of p120(ctn) in v-Src transfected L cells depends on its association with E-cadherin and reduces adhesion activity","volume":"114","author":"Ozawa","year":"2001","journal-title":"J Cell Sci"},{"key":"2022060701161263200_bib39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cels.2017.09.011","article-title":"A compendium of co-regulated protein complexes in breast cancer reveals collateral loss events","volume":"5","author":"Ryan","year":"2017","journal-title":"Cell Syst"},{"key":"2022060701161263200_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.devcel.2013.01.010","article-title":"Adhesion disengagement uncouples intrinsic and extrinsic forces to drive cytokinesis in epithelial tissues","volume":"24","author":"Guillot","year":"2013","journal-title":"Develop Cell"},{"key":"2022060701161263200_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/21541248.2014.1000699","article-title":"Myotonic dystrophy kinase-related Cdc42-binding kinases (MRCK), the ROCK-like effectors of Cdc42 and Rac1","volume":"6","author":"Zhao","year":"2015","journal-title":"Small GTPases"},{"key":"2022060701161263200_bib42","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.febslet.2011.03.054","article-title":"Chelerythrine perturbs lamellar actomyosin filaments by selective inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase","volume":"585","author":"Tan","year":"2011","journal-title":"FEBS Lett"},{"key":"2022060701161263200_bib43","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1242\/dmm.006395","article-title":"Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice","volume":"4","author":"Derksen","year":"2011","journal-title":"Dis Model Mech"},{"key":"2022060701161263200_bib44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ccr.2006.09.013","article-title":"Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis","volume":"10","author":"Derksen","year":"2006","journal-title":"Cancer Cell"},{"key":"2022060701161263200_bib45","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-12-4081","article-title":"A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models","volume":"73","author":"Zhang","year":"2013","journal-title":"Cancer Res"},{"key":"2022060701161263200_bib46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12964-014-0054-x","article-title":"A novel small-molecule MRCK inhibitor blocks cancer cell invasion","volume":"12","author":"Unbekandt","year":"2014","journal-title":"Cell Commun Signal"},{"key":"2022060701161263200_bib47","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0107","article-title":"Functional viability profiles of breast cancer","volume":"1","author":"Brough","year":"2011","journal-title":"Cancer Discov"},{"key":"2022060701161263200_bib48","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1535-7163.MCT-15-0554","article-title":"Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with dasatinib","volume":"15","author":"Miller","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2022060701161263200_bib49","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/emmm.201201250","article-title":"Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells","volume":"4","author":"Bajrami","year":"2012","journal-title":"EMBO Mol Med"},{"key":"2022060701161263200_bib50","doi-asserted-by":"crossref","first-page":"12117","DOI":"10.1073\/pnas.0702955104","article-title":"Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer","volume":"104","author":"Rottenberg","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161263200_bib51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/4\/498\/2942929\/498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/4\/498\/2942929\/498.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T14:17:57Z","timestamp":1660745877000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/4\/498\/9660\/E-Cadherin-ROS1-Inhibitor-Synthetic-Lethality-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,1]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0603","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.22532777.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532780.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532783.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532777","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532786","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532792.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532771.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532795.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532786.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532792","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532780","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532774.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532774","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532795","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532783","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532771","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6546827","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546827.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,1]]}}}